A multicenter, double-blind, follow-up trial evaluating the long-term safety of levetiracetam (1000 to 3000 mg/day oral b.i.d.) and carbamazepine (400 to 1200 mg/day oral b.i.d.), used as monotherapy in subjects (greater than or equal to 16 years) coming from the N01061 trial.

Trial Profile

A multicenter, double-blind, follow-up trial evaluating the long-term safety of levetiracetam (1000 to 3000 mg/day oral b.i.d.) and carbamazepine (400 to 1200 mg/day oral b.i.d.), used as monotherapy in subjects (greater than or equal to 16 years) coming from the N01061 trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Carbamazepine (Primary) ; Levetiracetam (Primary)
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 24 Jul 2007 The expected completion date for this trial is now 1 Nov 2005.
    • 16 Jul 2007 Status changed from in progress to completed.
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top